Boston Scientific (NYSE:BSX) Releases FY 2025 Earnings Guidance

Key Points

• Boston Scientific updated its FY 2025 earnings guidance, forecasting earnings per share between $3.020 and $3.040, exceeding the average consensus estimate of $2.980.
• The company also projects revenue to be around $20.1 billion, surpassing the consensus estimate of $19.9 billion.
• Currently, Boston Scientific holds a consensus rating of "Buy" from analysts, with two strong buy ratings and a target price increase to $132.00 from multiple firms.

Boston Scientific (NYSE:BSX - Get Free Report) updated its FY 2025 earnings guidance on Wednesday. The company provided earnings per share guidance of 3.020-3.040 for the period, compared to the consensus earnings per share estimate of 2.980. The company issued revenue guidance of $20.1 billion-$20.1 billion, compared to the consensus revenue estimate of $19.9 billion. Boston Scientific also updated its Q4 2025 guidance to 0.770-0.790 EPS.

Analyst Ratings Changes

Several equities analysts recently issued reports on BSX shares. Jefferies Financial Group reiterated a "hold" rating on shares of Boston Scientific in a research note on Monday, July 21st. Erste Group Bank cut Boston Scientific from a "buy" rating to a "hold" rating in a research report on Friday, October 3rd. Leerink Partners raised their price target on Boston Scientific from $127.00 to $128.00 and gave the stock an "outperform" rating in a report on Wednesday, October 1st. Raymond James Financial upped their price objective on Boston Scientific from $121.00 to $124.00 and gave the stock a "strong-buy" rating in a research note on Thursday, July 24th. Finally, BTIG Research increased their target price on Boston Scientific from $127.00 to $132.00 and gave the stock a "buy" rating in a research report on Wednesday, October 1st. Two investment analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, Boston Scientific presently has a consensus rating of "Buy" and a consensus price target of $121.61.

Boston Scientific Stock Performance

Shares of NYSE BSX opened at $99.88 on Wednesday. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49. Boston Scientific has a 52-week low of $80.64 and a 52-week high of $109.50. The stock has a market capitalization of $148.00 billion, a price-to-earnings ratio of 59.45, a PEG ratio of 2.42 and a beta of 0.61. The stock's fifty day simple moving average is $101.19 and its 200 day simple moving average is $101.83.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings data on Wednesday, October 22nd. The medical equipment provider reported $0.75 EPS for the quarter, topping analysts' consensus estimates of $0.71 by $0.04. The firm had revenue of $5.07 billion during the quarter, compared to analyst estimates of $4.97 billion. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The business's quarterly revenue was up 20.3% compared to the same quarter last year. During the same period last year, the company posted $0.63 EPS. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. As a group, sell-side analysts forecast that Boston Scientific will post 2.85 earnings per share for the current fiscal year.

Insider Buying and Selling at Boston Scientific

In related news, EVP Arthur C. Butcher sold 17,313 shares of the stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $104.63, for a total transaction of $1,811,459.19. Following the completion of the sale, the executive vice president owned 23,600 shares in the company, valued at $2,469,268. This represents a 42.32% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Yoshiaki Fujimori sold 2,901 shares of the firm's stock in a transaction that occurred on Tuesday, July 29th. The shares were sold at an average price of $106.99, for a total value of $310,377.99. Following the completion of the sale, the director directly owned 2,081 shares in the company, valued at $222,646.19. This trade represents a 58.23% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 174,214 shares of company stock valued at $17,972,457. Corporate insiders own 0.50% of the company's stock.

Hedge Funds Weigh In On Boston Scientific

Large investors have recently added to or reduced their stakes in the company. Evergreen Capital Management LLC raised its position in Boston Scientific by 4.3% in the second quarter. Evergreen Capital Management LLC now owns 7,868 shares of the medical equipment provider's stock worth $845,000 after purchasing an additional 327 shares in the last quarter. CANADA LIFE ASSURANCE Co grew its stake in shares of Boston Scientific by 5.6% in the 2nd quarter. CANADA LIFE ASSURANCE Co now owns 1,924,409 shares of the medical equipment provider's stock valued at $206,911,000 after purchasing an additional 101,925 shares during the period. MUFG Securities EMEA plc acquired a new position in shares of Boston Scientific in the 2nd quarter worth approximately $470,000. Resources Management Corp CT ADV lifted its position in shares of Boston Scientific by 5.7% during the 2nd quarter. Resources Management Corp CT ADV now owns 16,278 shares of the medical equipment provider's stock worth $1,748,000 after buying an additional 880 shares during the period. Finally, State of Tennessee Department of Treasury lifted its position in shares of Boston Scientific by 13.0% during the 2nd quarter. State of Tennessee Department of Treasury now owns 562,611 shares of the medical equipment provider's stock worth $60,430,000 after buying an additional 64,742 shares during the period. Institutional investors and hedge funds own 89.07% of the company's stock.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.